Parallel Import of Pharmaceutical Drugs to Russia (Q1 – Q2 2017)
Between January and June 2017, Russia imported 302,000 units of ready-made drugs worth 376.5 mln RUB (free circulation prices) without official permission of the rightholders. Over the year, the parallel import has risen by 49% in monetary terms and by 3 times in physical terms.
Over the period, imports of 21 trademarks could be deemed parallel, while in 2016 it was 10. Perfusion drug Custodiol (by Dr Franz Köhler Chemie) is the only one trademark has been subject to parallel import for the second consecutive year. In monetary terms, Jintropin (Somatropinum) by the British company Europharm is the leader in the parallel import, while the company is the leader in the total parallel import.
16 companies, usually small- and middle-sized ones with a short product line, participated in the parallel import. The top pharmaceutical companies in Russia have also been in, in particular Abbvie (Humira), Fresenius (Balance), Bayer (Alka-Seltzer.)
Between January and June 2017, the parallel imports included 10 countries, while in 2016 they were only 5. Georgia, Germany and Australia are the leaders, with more than 70% of the import. In monetary terms, the parallel import from Germany has risen by 89% since 2016.
Dynamics of parallel import of ready-made drugs to Russia, free circulation prices including customs clearance (2013 – 2016, Q1 – Q2 2017)